血浆肾素活性与降压药物选择的研究进展

摘要

高血压是世界范围内流行的疾病,原发性高血压病因未明,因此高血压治疗的目标也是血压控制和靶器官保护.高血压降压的个体化差异较大,且目前五大类降压药均为一线药物,为临床选择降压药带来困难.以血浆肾素活性(PRA)为依据将高血压分型,有利于指导临床医师合理选择降压药,增加高血压患者的依从性和降压达标率.现将PRA与降压药物选择的研究予以综述.%Hypertension is one of the most worldwide popular diseases.In fact, the etiology of essential hypertension is unknown, therefore the goal of treatment of hypertension is to control blood pressure value and target organ protection.The individual differences in blood pressure control is so great and the current guidelines state that all five classes of antihypertensive drugs are all first-line drugs, bringing difficulties for the clinical selection of antihypertensive drugs.The subtypes of hypertension classified based on plasma renin activity( PRA )will help guide the clinicians to a reasonable choice of antihypertensive drugs, increasing the compliance of patients with hypertension and antihypertensive compliance rate.The research update in theraputic effects of five types of hypotensive drugs based on the level of PRA in hypertensive patients will to be reviewed.